Oral immune‐related adverse events associated with PD‐1 inhibitor therapy: A case series
Muhammad Ali Shazib(Brigham and Women's Hospital), Alessandro Villa(Mario Negri Institute for Pharmacological Research), Arwa M. Farag(Tufts University), Sook‐Bin Woo(Dana-Farber Brigham Cancer Center), Hervé Sroussi(Harvard University), Ingrid Carvo(Harvard University), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Nathaniel S. Treister(Brigham and Women's Hospital), Robert I. Haddad(Georgetown University), Jonathan D. Schoenfeld(Brigham and Women's Hospital)
Cited by 53
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926